The molecular basis of chemoradiosensitivity in rectal cancer: Implications for personalized therapies

Langenbeck's Archives of Surgery

Volumn 397, Issue 4, 2012, Pages 543-555

  Grade, Marian ^a   Wolff, Hendrik A ^a   Gaedcke, Jochen ^a   Ghadimi, B Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Molecular biomarker; Preoperative chemoradiotherapy. Chemoradiosensitivity and chemoradioresistance; Rectal cancer; Response prediction

Indexed keywords

CETUXIMAB; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; SURVIVIN; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TCF4; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANEUPLOIDY; APOPTOSIS; CANCER ADJUVANT THERAPY; CHEMORADIOSENSITIVITY; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CODON; COMPARATIVE GENOMIC HYBRIDIZATION; CONTINUOUS INFUSION; COPY NUMBER VARIATION; DNA DAMAGE; DNA MICROARRAY; DNA REPAIR; DNA STRAND BREAKAGE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; PERSONALIZED MEDICINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIOSENSITIVITY; RECTUM CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL DESTRUCTION; TUMOR REGRESSION;

CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENETIC VARIATION; HUMANS; INDIVIDUALIZED MEDICINE; NEOADJUVANT THERAPY; PROGNOSIS; RADIATION TOLERANCE; RECTAL NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863989908     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-012-0929-5     Document Type: Review

References (98)

1. Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 69(10):613-616 (Pubitemid 12038080)
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638-646. doi:10.1056/NEJMoa010580
3. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R,Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731-1740. doi:10.1056/NEJMoa040694 (Pubitemid 39383208)
4. CunninghamD, AtkinW, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N (2010) Colorectal cancer. Lancet 375(9719):1030-1047. doi:10.1016/S0140- 6736(10)60353-4
5. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34):8688-8696. doi:10.1200/JCO.2005.02.1329 (Pubitemid 46211512)
6. Seiwert TY, Salama JK, Vokes EE (2007) The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 4(2):86-100. doi:10.1038/ncponc0714 (Pubitemid 46189538)
7. Katz D, Ito E, Liu FF (2009) On the path to seeking novel radiosensitizers. Int J Radiat Oncol Biol Phys 73(4):988-996. doi:10.1016/j.ijrobp.2008.12.002
8. Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11(4):239-253. doi:10.1038/nrc3007
9. Vaupel P, Schlenger K, Knoop C, Hockel M (1991) Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 51 (12):3316-3322
10. Steel GG, Peacock JH (1989) Why are some human tumours more radiosensitive than others? Radiother Oncol 15(1):63-72 (Pubitemid 19147621)
11. Zaider M, Hanin L (2011) Tumor control probability in radiation treatment. Med Phys 38(2):574-583
12. Weichselbaum RR, Little JB (1982) Radioresistance in some human tumor cells conferred in vitro by repair of potentially lethal X-ray damage. Radiology 145(2):511-513 (Pubitemid 12002911)
13. Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5(1):85-91 (Pubitemid 9120186)
14. Wolff HA, Daldrup B, Jung K, Overbeck T, Hennies S, Matthias C, Hess CF, Roedel RM, Christiansen H (2011) High-grade acute organ toxicity as positive prognostic factor in adjuvant radiation and chemotherapy for locally advanced head and neck cancer. Radiology 258(3):864-871. doi:10.1148/radiol.10100705
15. Cheng C, Pounds S (2007) False discovery rate paradigms for statistical analyses of microarray gene expression data. Bioinformation 1 (10):436-446
16. Quackenbush J (2006) Microarray analysis and tumor classification. N Engl J Med 354(23):2463-2472. doi:10.1056/ NEJMra042342 (Pubitemid 43855049)
17. van't Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452 (7187):564-570. doi:10.1038/nature06915 (Pubitemid 351483370)
18. Kuremsky JG, Tepper JE, McLeod HL (2009) Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74(3):673-688. doi:10.1016/j. ijrobp.2009.03.003
19. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G (2009) Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 35(3):201-209. doi:10.1016/j.ctrv. 2008.10.006
20. Brettingham-Moore KH, Duong CP, Heriot AG, Thomas RJ, Phillips WA (2011) Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils. Ann Surg Oncol 18(5):1484-1491. doi:10.1245/s10434-010-1433-1
21. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Fuzesi L, Langer C, Becker H, Liersch T, Ried T (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23(9):1826-1838 (Pubitemid 46217459)
22. Liersch T, Grade M, Gaedcke J, Varma S, Difilippantonio MJ, Langer C, Hess CF, Becker H, Ried T, Ghadimi BM (2009) Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence. Cancer Genet Cytogenet 190(2):57-65. doi:10.1016/j. cancergencyto.2008.11.011
23. Watanabe T, Komuro Y, Kiyomatsu T, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Yamamoto Y, Shirane M, Muto T, Nagawa H (2006) Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 66(7):3370-3374. doi:10.1158/ 0008-5472.CAN-05-3834
24. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, Jang SG, Park JH, Kim DY, Jung KH, Choi HS, Jeong SY, Sohn DK, Kim DW, Park JG (2007) Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50 (9):1342-1353. doi:10.1007/s10350-007-277-7 (Pubitemid 47472394)
25. Rimkus C, Friederichs J, Boulesteix AL, Theisen J, Mages J, Becker K, Nekarda H, Rosenberg R, Janssen KP, Siewert JR (2008) Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 6(1):53-61. doi:10.1016/j. cgh.2007.10.022 (Pubitemid 350309530)
26. Brettingham-Moore KH, Duong CP, Greenawalt DM, Heriot AG, Ellul J, Dow CA, Murray WK, Hicks RJ, Tjandra J, Chao M, Bui A, Joon DL, Thomas RJ, Phillips WA (2011) Pretreatment transcriptional profiling for predicting response to neoadjuvant chemoradiotherapy in rectal adenocarcinoma. Clin Cancer Res 17 (9):3039-3047. doi:10.1158/1078-0432.CCR-10-2915
27. Borst P, Wessels L (2010) Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 9(24):4836-4840
28. Koscielny S (2010) Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2 (14):14ps12. doi:10.1126/ scitranslmed.3000313
29. Gonen M (2009) Statistical aspects of gene signatures and molecular targets. Gastrointest Cancer Res 3(2 Suppl):S19-S21
30. Johannes M, Brase JC, Frohlich H, Gade S, Gehrmann M, Falth M, Sultmann H, Beissbarth T (2010) Integration of pathway knowledge into a reweighted recursive feature elimination approach for risk stratification of cancer patients. Bioinformatics 26(17):2136-2144. doi:10.1093/bioinformatics/btq345
31. Porzelius C, Johannes M, Binder H, Beissbarth T (2011) Leveraging external knowledge on molecular interactions in classification methods for risk prediction of patients. Biom J 53(2):190-201. doi:10.1002/bimj.201000155
32. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009. doi:10.1056/ NEJMoa021967 (Pubitemid 35461656)
33. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530-536. doi:10.1038/415530a (Pubitemid 34130608)
34. Buyse M, Loi S, Veer L van't, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17):1183-1192. doi:10.1093/jnci/ djj329 (Pubitemid 44390989)
35. Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL,Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van deVijver MJ, Linn SC (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8 (12):1079-1087. doi:10.1016/S1470-2045(07)70346-7 (Pubitemid 350182954)
36. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6(10):813-823. doi:10.1038/ nrc1951 (Pubitemid 44450469)
37. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515-527. doi:10.1016/j. ccr.2006.10.008 (Pubitemid 44854747)
38. Benson JD, Chen YN, Cornell-Kennon SA, Dorsch M, Kim S, Leszczyniecka M, Sellers WR, Lengauer C (2006) Validating cancer drug targets. Nature 441(7092):451-456. doi:10.1038/nature04873 (Pubitemid 44050140)
39. Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T (2009) Sample type bias in the analysis of cancer genomes. Cancer Res 69(14):5630-5633. doi:10.1158/0008-5472.CAN-09-1055
40. Eschrich S, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Torres-Roca JF (2009) Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 75(2):497-505. doi:10.1016/j. ijrobp.2009.05.056
41. Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF (2009) A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75(2):489-496. doi:10.1016/j.ijrobp.2009.06.014
42. Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, Cantor AB, Scuto A, Li C, Zhang S, Jove R, Yeatman T (2005) Prediction of radiation sensitivity using a gene expression classifier. Cancer Res 65(16):7169-7176. doi:10.1158/0008-5472.CAN-05-0656 (Pubitemid 41161247)
43. Spitzner M, Emons G, Kramer F, Gaedcke J, Rave-Frank M, Scharf JG, Burfeind P, Becker H, Beissbarth T, Ghadimi BM, Ried T, Grade M (2010) A gene expression signature for chemoradiosensitivity of colorectal cancer cells. Int J Radiat Oncol Biol Phys 78(4):1184-1192. doi:10.1016/j.ijrobp.2010.06.023
44. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489-499. doi:10.1038/nrc2645
45. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361 (25):2449-2460. doi:10.1056/NEJMra0804588
46. Albertson DG, Collins C, McCormick F, Gray JW (2003) Chromosome aberrations in solid tumors. Nat Genet 34(4):369-376. doi:10.1038/ng1215 (Pubitemid 36935328)
47. Grade M, Becker H, Liersch T, Ried T, Ghadimi BM (2006) Molecular cytogenetics: genomic imbalances in colorectal cancer and their clinical impact. Cell Oncol 28(3):71-84 (Pubitemid 43999883)
48. Ried T, Knutzen R, Steinbeck R, Blegen H, Schrock E, Heselmeyer K, du Manoir S, Auer G (1996) Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 15 (4):234-245. doi:10.1002/(SICI)1098-2264(199604)15: 4<234:: AID-GCC5>3.0.CO;2-2 (Pubitemid 26115931)
49. Grade M, Ghadimi BM, Varma S, Simon R, Wangsa D, Barenboim-Stapleton L, Liersch T, Becker H, Ried T, Difilippantonio MJ (2006) Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/ beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 66(1):267-282 (Pubitemid 43166033)
50. Grade M, Hormann P, Becker S, Hummon AB, Wangsa D, Varma S, Simon R, Liersch T, Becker H, Difilippantonio MJ, Ghadimi BM, Ried T (2007) Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 67(1):41-56 (Pubitemid 46142758)
51. Grade M, Gaedcke J, Wangsa D, Varma S, Beckmann J, Liersch T, Hess C, Becker H, Difilippantonio MJ, Ried T, Ghadimi BM (2009) Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. Cancer Genet Cytogenet 193(1):19-28. doi:10.1016/j. cancergencyto.2009.03.016
52. Chen Z, Liu Z, Li W, Qu K, Deng X, Varma MG, Fichera A, Pigazzi A, Garcia-Aguilar J (2011) Chromosomal copy number alterations are associated with tumor response to chemoradiation in locally advanced rectal cancer. Genes Chromosomes Cancer 50 (9):689-699. doi:10.1002/gcc.20891
53. Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3(6):459-465. doi:10.1038/nrc1097 (Pubitemid 37328850)
54. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11(11):761-774. doi:10.1038/nrc3106
55. McKenna WG, Weiss MC, Bakanauskas VJ, Sandler H, Kelsten ML, Biaglow J, Tuttle SW, Endlich B, Ling CC, Muschel RJ (1990) The role of the H-ras oncogene in radiation resistance and metastasis. Int J Radiat Oncol Biol Phys 18(4):849-859 (Pubitemid 20154043)
56. Miller AC, Kariko K, Myers CE, Clark EP, Samid D (1993) Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. Int J Cancer 53(2):302-307 (Pubitemid 23042883)
57. Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ (1998) Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 58(8):1754-1761 (Pubitemid 28215105)
58. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, McKenna WG (2001) The Ras radiation resistance pathway. Cancer Res 61(10):4278-4282 (Pubitemid 32721000)
59. Luna-Perez P, Segura J, Alvarado I, Labastida S, Santiago-Payan H, Quintero A (2000) Specific c-K-ras gene mutations as a tumorresponse marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 7(10):727-731
60. Ondrejka SL, Schaeffer DF, Jakubowski MA, Owen DA, Bronner MP (2011) Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing? Am J Surg Pathol 35 (9):1327-1330. doi:10.1097/PAS.0b013e3182253800
61. Zauber NP, Marotta SP, Berman E, Grann A, Rao M, Komati N, Ribiero K, Bishop DT (2009) Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. Int J Radiat Oncol Biol Phys. doi:10.1016/j. ijrobp.2008.08.020
62. Gaedcke J, GradeM, Jung K, SchirmerM, Jo P, Obermeyer C,Wolff HA, Herrmann MK, Beissbarth T, Becker H, Ried T, Ghadimi M (2010) KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 94 (1):76-81. doi:10.1016/j.radonc.2009.10. 001
63. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, Marcet J, Pastor C (2011) Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg 254(3):486-492. doi:10.1097/SLA.0b013e31822b8cfa, discussion 492-483
64. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R (2000) K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60(23):6750-6756
65. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, Tomasino RM, Labianca R, Gebbia N, Russo A (2002) Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13(9):1438-1446
66. Horsch M, Recktenwald CV, Schadler S, Hrabe de Angelis M, Seliger B, Beckers J (2009) Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study. Br J Cancer 100(4):656-662. doi:10.1038/sj.bjc. 6604882
67. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S (2010) Association of KRASp.G13D mutation with outcome in patients with chemotherapyrefractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16):1812-1820. doi:10.1001/jama.2010.1535
68. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rodel C (2010) Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: a pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 78(2):472-478. doi:10.1016/j.ijrobp.2009.07.1718
69. Debucquoy A, Machiels JP, McBride WH, Haustermans K (2010) Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. Clin Cancer Res 16(10):2709-2714. doi:10.1158/1078-0432.CCR-09-1622
70. Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. J Clin Invest 118 (5):1590-1605. doi:10.1172/JCI34772 (Pubitemid 351632361)
71. Botstein D, Risch N (2003) Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet 33(Suppl):228-237. doi:10.1038/ng1090 (Pubitemid 36278833)
72. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, Martin L, Sellick G, Jaeger E, Hubner R, Wild R, Rowan A, Fielding S, Howarth K, Silver A, Atkin W, Muir K, Logan R, Kerr D, Johnstone E, Sieber O, Gray R, Thomas H, Peto J, Cazier JB, Houlston R (2007) A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 39(8):984-988. doi:10.1038/ng2085 (Pubitemid 47185182)
73. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, Sundararajan S, Roumy S, Olivier JF, Robidoux F, Sladek R, Montpetit A, Campbell P, Bezieau S, O'Shea AM, Zogopoulos G, Cotterchio M, Newcomb P, McLaughlin J, Younghusband B, Green R, Green J, Porteous ME, Campbell H, Blanche H, Sahbatou M, Tubacher E, Bonaiti-Pellie C, Buecher B, Riboli E, Kury S, Chanock SJ, Potter J, Thomas G, Gallinger S, Hudson TJ, Dunlop MG (2007) Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39(8):989-994. doi:10.1038/ng2089 (Pubitemid 47185183)
74. Haiman CA, Le Marchand L, Yamamato J, Stram DO, Sheng X, Kolonel LN, Wu AH, Reich D, Henderson BE (2007) A common genetic risk factor for colorectal and prostate cancer. Nat Genet 39 (8):954-956. doi:10.1038/ng2098 (Pubitemid 47185184)
75. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348(6):529-537. doi:10.1056/NEJMra020021 (Pubitemid 36159889)
76. Evans WE, McLeod HL (2003) Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348(6):538-549. doi:10.1056/NEJMra020526 (Pubitemid 36159890)
77. Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PD, Dunning AM, West CM (2012) Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol 13(1):65-77. doi:10.1016/S1470-2045(11)70302-3
78. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19(6):1779-1786 (Pubitemid 32230880)
79. Terrazzino S, Agostini M, Pucciarelli S, Pasetto LM, Friso ML, Ambrosi A, Lisi V, Leon A, Lise M, Nitti D (2006) A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 16(11):817-824. doi:10.1097/ 01.fpc.0000230412.89973.c0 (Pubitemid 44632296)
80. Conradi LC, Bleckmann A, Schirmer M, Sprenger T, Jo P, Homayounfar K, Wolff HA, Rothe H, Middel P, Becker H, Ghadimi MB, Beissbarth T, Liersch T (2011) Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol 18(9):2442-2452. doi:10.1245/s10434-011-1608-4
81. Spindler KL, Nielsen JN, Lindebjerg J, Jakobsen A (2007) Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 50(9):1363-1369. doi:10.1007/s10350-007-0264-z (Pubitemid 47472390)
82. Stoehlmacher J, Goekkurt E, Mogck U, Aust DE, Kramer M, Baretton GB, Liersch T, Ehninger G, Jakob C (2008) Thymidylate synthase genotypes and tumour regression in stage II/ III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett 272(2):221-225. doi:10.1016/j. canlet.2008.07.008
83. Hur H, Kang J, Kim NK, Min BS, Lee KY, Shin SJ, Keum KC, Choi J, Kim H, Choi SH, Lee MY (2011) Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 81(3):669-676. doi:10.1016/j. ijrobp.2010.06.049
84. Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW, McLeod HL (2011) Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 29(7):875-883. doi:10.1200/JCO.2010.32.3212
85. Schirmer MA, Nadine Mergler CP, Rave-Frank M, Herrmann MK, Hennies S, Gaedcke J, Conradi LC, Jo P, Beissbarth T, Hess CF, Becker H, Ghadimi M, Brockmoller J, Christiansen H, Wolff HA (2011) Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant. Int J Radiat Oncol Biol Phys. doi:10.1016/j. ijrobp.2011.05.063
86. Berardi R, Maccaroni E, Onofri A, Giampieri R, Pistelli M, Bittoni A, Scartozzi M, Pierantoni C, Mandolesi A, Bearzi I, Cascinu S (2009) Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: part 2. Expert Opin Pharmacother 10(15):2467-2478. doi:10.1517/14656560903143784
87. Kapur P (2011) Tailoring treatment of rectal adenocarcinoma: immunohistochemistry for predictive biomarkers. Anticancer Drugs 22(4):362-370. doi:10.1097/CAD.0b013e3283433764
88. Petrocca F, Lieberman J (2011) Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol 29(6):747-754. doi:10.1200/JCO.2009.27.6287
89. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59-67. doi:10.1038/nrc2966
90. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8(1):61-70. doi:10.1038/nrc2293
91. Rodel C,Haas J, Groth A,Grabenbauer GG, Sauer R, Rodel F (2003) Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55(5):1341-1347 (Pubitemid 36338302)
92. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C (2005) Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65(11):4881-4887. doi:10.1158/0008-5472.CAN-04-3028 (Pubitemid 40740827)
93. Capalbo G, Dittmann K, Weiss C, Reichert S, Hausmann E, Rodel C, Rodel F (2010) Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int J Radiat Oncol Biol Phys 77(1):226-234. doi:10.1016/j.ijrobp.2009. 12.001
94. Rodel F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T, Fulda S, Rodel C (2011) The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr Med Chem 18 (2):191-199
95. Sprenger T, Rodel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, Wolff HA, Ghadimi BM, Yildrim M, Becker H, Rodel C, Liersch TFailure of down-regulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival Clin Cancer Res. doi:10.1158/1078-0432.CCR-10-2592
96. Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5 (9):691-701. doi:10.1038/nrg1427 (Pubitemid 39150127)
97. Clevers H (2006) Wnt/beta-catenin signaling in development and disease. Cell 127(3):469-480. doi:10.1016/j.cell.2006.10.018 (Pubitemid 44647433)
98. Kendziorra E, Ahlborn K, Spitzner M, Rave-Frank M, Emons G, Gaedcke J, Kramer F, Wolff HA, Becker H, Beissbarth T, Ebner R, Ghadimi BM, Pukrop T, Ried T, Grade M (2011) Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 32(12):1824-1831. doi:10.1093/carcin/bgr222